MX2022015439A - Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus. - Google Patents

Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus.

Info

Publication number
MX2022015439A
MX2022015439A MX2022015439A MX2022015439A MX2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A MX 2022015439 A MX2022015439 A MX 2022015439A
Authority
MX
Mexico
Prior art keywords
methods
infection
inhibiting
materials
coronavirus
Prior art date
Application number
MX2022015439A
Other languages
English (en)
Spanish (es)
Inventor
Eva A Berkes
Nicholas T Monsul
Frederick T Boehm
Yu-Hsien Liao
Original Assignee
Quorum Innovations Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quorum Innovations Llc filed Critical Quorum Innovations Llc
Publication of MX2022015439A publication Critical patent/MX2022015439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022015439A 2020-06-06 2021-06-07 Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus. MX2022015439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (1)

Publication Number Publication Date
MX2022015439A true MX2022015439A (es) 2023-03-22

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015439A MX2022015439A (es) 2020-06-06 2021-06-07 Materiales y metodos para inhibir una infeccion virica, incluida una infeccion por coronavirus.

Country Status (11)

Country Link
US (3) US11826390B2 (cg-RX-API-DMAC7.html)
EP (1) EP4161558A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023529152A (cg-RX-API-DMAC7.html)
KR (1) KR20230025853A (cg-RX-API-DMAC7.html)
CN (1) CN116133669A (cg-RX-API-DMAC7.html)
AU (1) AU2021286002A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024911A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180737A1 (cg-RX-API-DMAC7.html)
IL (1) IL298401A (cg-RX-API-DMAC7.html)
MX (1) MX2022015439A (cg-RX-API-DMAC7.html)
WO (1) WO2021248111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293368B2 (en) * 2019-11-26 2026-05-01 Quorum Innovations Llc New barrier and protective preparations and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
KR101300086B1 (ko) 2005-10-06 2013-08-30 프로비 아베 자가면역질환의 치료를 위한 락토바실러스의 용도
AU2008361375B2 (en) * 2008-09-04 2014-05-22 Om Pharma Immunomodulatory extracts from Lactobacillus bacteria and methods of manufacturing and use thereof
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
WO2017015275A1 (en) * 2015-07-20 2017-01-26 Quorum Innovations, Llc Materials and methods for improving immune responses and the skin and/or mucosal barrier function
CN109562140B (zh) 2016-06-03 2023-01-03 霍夫耳科研究所 用于内耳感觉毛细胞再生/替换的联合疗法
US12195502B2 (en) * 2020-05-06 2025-01-14 Quorum Innovations, Llc Protein, and therapeutic and cosmetic uses thereof

Also Published As

Publication number Publication date
KR20230025853A (ko) 2023-02-23
WO2021248111A9 (en) 2022-12-22
US20230136276A1 (en) 2023-05-04
AU2021286002A1 (en) 2023-01-19
EP4161558A4 (en) 2024-06-19
US20260224649A1 (en) 2026-08-06
IL298401A (en) 2023-01-01
WO2021248111A1 (en) 2021-12-09
EP4161558A1 (en) 2023-04-12
US12653849B2 (en) 2026-06-16
JP2023529152A (ja) 2023-07-07
US20240075083A1 (en) 2024-03-07
CA3180737A1 (en) 2021-12-09
US11826390B2 (en) 2023-11-28
CN116133669A (zh) 2023-05-16
BR112022024911A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
WO2021188969A3 (en) Coronavirus vaccines and methods of use
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
MX379160B (es) Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infección respiratoria por virus.
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
HUP9802525A1 (hu) Hüvelyfertőzések kezelésére szolgáló, lactobacillus tartalmú gyógyászati készítmények
MX2025000629A (es) Cepas de lactobacillus salivarius y usos de las mismas
MX395076B (es) COMPOSICIÓN A BASE DE UN EXTRACTO DE BIOACTIVO DE L. fermentum PARA USARSE EN EL TRATAMIENTO DE CONDICIONES DERMATOLOGICAS HUMANAS.
WO2021004958A3 (en) Compositions comprising bacterial strains
EP4364583A4 (en) COMPOSITION WITH THREE LACTOBACILLUS SP. STRAINS AND ITS USE
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
PH12018550110B1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
MX2022001973A (es) Formulaciones para la prevención o reducción de infecciones por c. difficile.
ZA202306411B (en) Novel protective barrier compositions, and uses thereof
ZA202203363B (en) Immunogenic compositions
MX2022010877A (es) Cepas bacterianas y composiciones de las mismas para uso oral en el tratamiento de infecciones virales del aparato respiratorio.
ITMI20011632A0 (it) Composizione solida contenente spore di batteri non patogeni del genere bacillus
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
ZA202303253B (en) Modified mycobacterium bovis vaccines
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
MX2023014940A (es) Bacteriofagos contra enterococci resistentes a la vancomicina.
MX2023007992A (es) Compuestos cuadracíclicos fundidos, composiciones y usos de los mismos.